These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39064468)

  • 1. Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.
    Doello K; Chico MA; Quiñonero F; Ortiz R; Prados J; Mesas C; Melguizo C
    Medicina (Kaunas); 2024 Jun; 60(7):. PubMed ID: 39064468
    [No Abstract]   [Full Text] [Related]  

  • 2. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors.
    Streuli J; Harris AG; Cottiny C; Allagnat F; Daly AF; Grouzmann E; Abid K
    Neuropeptides; 2018 Apr; 68():84-89. PubMed ID: 29523357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis.
    Imhof AK; Glück L; Gajda M; Lupp A; Bräuer R; Schaible HG; Schulz S
    Arthritis Rheum; 2011 Aug; 63(8):2352-62. PubMed ID: 21506098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine tumours - Medical therapy: Biological.
    Rinke A; Krug S
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
    Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
    Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.
    Heidari P; Wehrenberg-Klee E; Habibollahi P; Yokell D; Kulke M; Mahmood U
    Cancer Res; 2013 Dec; 73(23):6865-73. PubMed ID: 24080280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
    Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
    Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
    Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
    Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor.
    Lehmann A; Kliewer A; Schütz D; Nagel F; Stumm R; Schulz S
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):44-51. PubMed ID: 24565897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
    Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.
    Weich A; Rogoll D; Peschka M; Weich W; Pongracz J; Brand M; Fröhlich M; Serfling SE; Rowe SP; Kosmala A; Reiter FP; Meining A; Werner RA; Scheurlen M
    Nucl Med Commun; 2023 Apr; 44(4):259-269. PubMed ID: 36804512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.